Skip to main content

Expression of carbonic anhydrase 9 is a novel prognostic marker in resectable hepatocellular carcinoma

Virchows Archiv volume 466, pages 403–413 (2015)Cite this article

Abstract

Carbonic anhydrase 9 (CA9), which regulates cellular proliferation and the acid-base balance, is known as prognostic factor in various types of cancer. The aim of this study is to investigate the clinical implications of CA9 expression in patients with hepatocellular carcinoma. Immunohistochemical staining for CA9 was performed on tissue microarrays of hepatocellular carcinoma and paired non-neoplastic liver tissue from a training cohort of 838 patients and a validation cohort of 225 patients. Membranous staining in more than 5 % of the tumor cells was considered to indicate CA9 positivity. The prognostic value of CA9 expression was statistically evaluated. In the training cohort, CA9 positivity (181 cases, 21.5 %) was significantly correlated with shorter overall survival (OS; p < 0.001) and recurrence-free survival (RFS; p = 0.004). In multivariate analysis, CA9 positivity was independently associated with reduced OS (p = 0.023), but not significantly associated with RFS (p = 0.384). These results were validated in an additional cohort (CA9 positivity in 35 cases, 15.6 %; OS, p = 0.015; RFS, p = 0.979). Pooled cohort analysis showed that this predictor was independently associated with higher mortality (OS; p < 0.001). These data indicate that CA9 expression is a poor prognostic factor in resectable hepatocellular carcinoma (HCC) patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Bosch FX, Ribes J, Cleries R, Diaz M (2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9:191–211. doi:10.1016/j.cld.2004.12.009

    Article  PubMed  Google Scholar 

  2. Shaw JJ, Shah SA (2011) Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean? Expert Rev Gastroenterol Hepatol 5:365–370. doi:10.1586/egh.11.20

    Article  PubMed  Google Scholar 

  3. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907–1917. doi:10.1016/S0140-6736(03)14964-1

    Article  PubMed  Google Scholar 

  4. Fong ZV, Tanabe KK (2014) The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review. Cancer. doi:10.1002/cncr.28730

    Google Scholar 

  5. Harding JJ, Abou-Alfa GK (2014) Treating advanced hepatocellular carcinoma: how to get out of first gear. Cancer. doi:10.1002/cncr.28850

    PubMed Central  Google Scholar 

  6. Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP (2003) Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 197:753–758. doi:10.1016/j.jamcollsurg.2003.07.003

    Article  PubMed  Google Scholar 

  7. Tung-Ping Poon R, Fan ST, Wong J (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232:10–24

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Pazo-Cid RA, Lanzuela M, Esquerdo G, Perez-Gracia JL, Anton A, Amigo G, Trufero JM, Garcia-Otin AL, Martin-Duque P (2012) Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). Clin Transl Oncol 14:564–574. doi:10.1007/s12094-012-0842-y

    Article  CAS  PubMed  Google Scholar 

  9. Semela D, Dufour JF (2004) Angiogenesis and hepatocellular carcinoma. J Hepatol 41:864–880. doi:10.1016/j.jhep.2004.09.006

    Article  PubMed  Google Scholar 

  10. Kockar F, Yildrim H, Sagkan RI, Hagemann C, Soysal Y, Anacker J, Hamza AA, Vordermark D, Flentje M, Said HM (2012) Hypoxia and cytokines regulate carbonic anhydrase 9 expression in hepatocellular carcinoma cells in vitro. World J Clin Oncol 3:82–91. doi:10.5306/wjco.v3.i6.82

    Article  PubMed Central  PubMed  Google Scholar 

  11. Luong-Player A, Liu H, Wang HL, Lin F (2014) Immunohistochemical reevaluation of carbonic anhydrase IX (CA IX) expression in tumors and normal tissues. Am J Clin Pathol 141:219–225. doi:10.1309/AJCPVJDS28KNYZLD

    Article  PubMed  Google Scholar 

  12. Dorai T, Sawczuk IS, Pastorek J, Wiernik PH, Dutcher JP (2005) The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer 41:2935–2947. doi:10.1016/j.ejca.2005.09.011

    Article  CAS  PubMed  Google Scholar 

  13. Stewart DJ, Nunez MI, Behrens C, Liu D, Lin YH, Lee JJ, Roth J, Heymach J, Swisher SG, Hong WK, Wistuba II (2014) Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer. J Thorac Oncol 9:675–684. doi:10.1097/JTO.0000000000000148

    Article  CAS  PubMed  Google Scholar 

  14. Liu Z, Yang Z, Jiang S, Zou Q, Yuan Y, Li J, Li D, Liang L, Chen M, Chen S (2014) Paxillin and carbonic anhydrase IX are prognostic markers in gallbladder squamous cell/adenosquamous carcinomas and adenocarcinomas. Histopathology 64:921–934. doi:10.1111/his.12341

    Article  PubMed  Google Scholar 

  15. Furjelova M, Kovalska M, Jurkova K, Horacek J, Carbolova T, Adamkov M (2014) Carbonic anhydrase IX: a promising diagnostic and prognostic biomarker in breast carcinoma. Acta Histochem 116:89–93. doi:10.1016/j.acthis.2013.05.009

    Article  CAS  PubMed  Google Scholar 

  16. Choschzick M, Woelber L, Gieseking F, Oosterwijk E, Tennstedt P (2014) Carbonic anhydrase IX is strongly overexpressed in adenocarcinoma in situ of the cervix uteri. Histopathology 64:600–602. doi:10.1111/his.12288

    Article  PubMed  Google Scholar 

  17. Wachters JE, Schrijvers ML, Slagter-Menkema L, Mastik M, de Bock GH, Langendijk JA, Kluin PM, Schuuring E, van der Laan BF, van der Wal JE (2013) Prognostic significance of HIF-1a, CA-IX, and OPN in T1-T2 laryngeal carcinoma treated with radiotherapy. Laryngoscope 123:2154–2160

    Article  PubMed  Google Scholar 

  18. Klimowicz AC, Bose P, Petrillo SK, Magliocco AM, Dort JC, Brockton NT (2013) The prognostic impact of a combined carbonic anhydrase IX and Ki67 signature in oral squamous cell carcinoma. Br J Cancer 109:1859–1866. doi:10.1038/bjc.2013.533

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Kaya AO, Gunel N, Benekli M, Akyurek N, Buyukberber S, Tatli H, Coskun U, Yildiz R, Yaman E, Ozturk B (2012) Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients. J BUON 17:663–668

    CAS  PubMed  Google Scholar 

  20. Korkeila E, Talvinen K, Jaakkola PM, Minn H, Syrjanen K, Sundstrom J, Pyrhonen S (2009) Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer. Br J Cancer 100:874–880. doi:10.1038/sj.bjc.6604949

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Potter CP, Harris AL (2003) Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 89:2–7. doi:10.1038/sj.bjc.6600936

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Yu SJ, Yoon JH, Lee JH, Myung SJ, Jang ES, Kwak MS, Cho EJ, Jang JJ, Kim YJ, Lee HS (2011) Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis. Acta Pharmacol Sin 32:912–920. doi:10.1038/aps.2011.24

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Al-Ahmadie HA, Alden D, Qin LX, Olgac S, Fine SW, Gopalan A, Russo P, Motzer RJ, Reuter VE, Tickoo SK (2008) Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. Am J Surg Pathol 32:377–382. doi:10.1097/PAS.0b013e3181570343

    Article  PubMed  Google Scholar 

  24. Dubois L, Peeters SG, van Kuijk SJ, Yaromina A, Lieuwes NG, Saraya R, Biemans R, Rami M, Parvathaneni NK, Vullo D, Vooijs M, Supuran CT, Winum JY, Lambin P (2013) Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: a new concept of dual targeting drugs. Radiother Oncol 108:523–528. doi:10.1016/j.radonc.2013.06.018

    Article  CAS  PubMed  Google Scholar 

  25. Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL, O’Byrne KJ (2003) Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 21:473–482

    Article  CAS  PubMed  Google Scholar 

  26. Choschzick M, Oosterwijk E, Muller V, Woelber L, Simon R, Moch H, Tennstedt P (2011) Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Arch 459:193–200. doi:10.1007/s00428-011-1105-y

    Article  CAS  PubMed  Google Scholar 

  27. Woelber L, Kress K, Kersten JF, Choschzick M, Kilic E, Herwig U, Lindner C, Schwarz J, Jaenicke F, Mahner S, Milde-Langosch K, Mueller V, Ihnen M (2011) Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer. BMC Cancer 11:12. doi:10.1186/1471-2407-11-12

    Article  PubMed Central  PubMed  Google Scholar 

  28. Kappler M, Taubert H, Holzhausen HJ, Reddemann R, Rot S, Becker A, Kuhnt T, Dellas K, Dunst J, Vordermark D, Hansgen G, Bache M (2008) Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters. Strahlenther Onkol 184:393–399

    Article  PubMed  Google Scholar 

  29. Gigante M, Li G, Ferlay C, Perol D, Blanc E, Paul S, Zhao A, Tostain J, Escudier B, Negrier S, Genin C (2012) Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy. Anticancer Res 32:5447–5451

    CAS  PubMed  Google Scholar 

  30. Li G, Feng G, Gentil-Perret A, Genin C, Tostain J (2008) Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J Urol 180:510–513. doi:10.1016/j.juro.2008.04.024, discussion 513–514

    Article  CAS  PubMed  Google Scholar 

  31. Fidan E, Mentese A, Ozdemir F, Deger O, Kavgaci H, Caner Karahan S, Aydin F (2013) Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer. Med Oncol 30:540. doi:10.1007/s12032-013-0540-9

    Article  PubMed  Google Scholar 

  32. Kock L, Mahner S, Choschzick M, Eulenburg C, Milde-Langosch K, Schwarz J, Jaenicke F, Muller V, Woelber L (2011) Serum carbonic anhydrase IX and its prognostic relevance in vulvar cancer. Int J Gynecol Cancer 21:141–148. doi:10.1097/IGC.0b013e318204c34f

    Article  PubMed  Google Scholar 

  33. Gieling RG, Williams KJ (2013) Carbonic anhydrase IX as a target for metastatic disease. Bioorg Med Chem 21:1470–1476. doi:10.1016/j.bmc.2012.09.062

    Article  CAS  PubMed  Google Scholar 

  34. Gieling RG, Babur M, Mamnani L, Burrows N, Telfer BA, Carta F, Winum JY, Scozzafava A, Supuran CT, Williams KJ (2012) Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J Med Chem 55:5591–5600. doi:10.1021/jm300529u

    Article  CAS  PubMed  Google Scholar 

  35. Carradori S (2013) Selective carbonic anhydrase IX inhibitors based on coumarin scaffold as promising antimetastatic agents: WO2012070024. Expert Opin Ther Pat 23:751–756. doi:10.1517/13543776.2013.769523

    Article  CAS  PubMed  Google Scholar 

  36. Colinas PA (2013) Novel sulfonamide compounds for inhibition of metastatic tumor growth (WO2012021963). Expert Opin Ther Pat 23:761–763. doi:10.1517/13543776.2013.789023

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

The authors declare that they have no conflict of interest.

Author information

Affiliations

  1. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-Gu, 138-736, Seoul, South Korea

    Hyo Jeong Kang, Chang Ohk Sung & Eunsil Yu

  2. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

    Il Hwan Kim

  3. Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

    Ju Hyun Shim

Authors
  1. Hyo Jeong Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Il Hwan Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chang Ohk Sung
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ju Hyun Shim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eunsil Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eunsil Yu.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kang, H.J., Kim, I.H., Sung, C.O. et al. Expression of carbonic anhydrase 9 is a novel prognostic marker in resectable hepatocellular carcinoma. Virchows Arch 466, 403–413 (2015). https://doi.org/10.1007/s00428-014-1709-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-014-1709-0

Keywords

  • Hepatocellular carcinoma
  • Liver
  • CA9
  • Prognosis